idh inhibitors

What are the Common IDH Inhibitors?

Several IDH inhibitors are currently in various stages of clinical development or have received regulatory approval. Notable examples include:
Ivosidenib (IDH1 inhibitor)
Enasidenib (IDH2 inhibitor)
Other investigational agents targeting both IDH1 and IDH2 mutations
These agents have been primarily studied in hematologic malignancies and are expanding into solid tumors.

Frequently asked queries:

What are IDH Inhibitors?
How do IDH Mutations Contribute to Cancer?
Which Cancers are Treated with IDH Inhibitors?
What are the Common IDH Inhibitors?
What is the Mechanism of Action of IDH Inhibitors?
What are the Clinical Benefits and Limitations?
What are the Side Effects and Risks?
Can CDKN1C also have oncogenic properties?
Why is Moisturizing Important for Cancer Patients?
What Role Does Nutrition Play in Managing Fatigue?
Why is Intrathecal Treatment Used in Cancer?
Is There a Relationship Between Body Temperature and Cancer Metabolism?
What are Ototoxic Drugs?
What are the Common Techniques Used?
What Types of DSS are Used in Cancer Care?
How Can Patients Prevent Claim Denials?
What Types of Cancer Are Most Associated with Ischemic Stroke?
How Can Patients Prepare for Cancer Surgery?
How are Masses Diagnosed?
What Role Does Socioeconomic Status Play in Patient Harm?
Top Searches
Brain Tumor Breast cancer cancer Cancer Diagnostics Cancer Genomics Chemotherapy Essential Thrombocythemia hepatocellular carcinoma Lung Cancer Molecular Biomarkers Nanotechnology Non-Hodgkin’s Lymphoma Radiation-Induced Malignancies
Follow Us

Partnered Content Networks

Relevant Topics